Smith & Nephew to Acquire Osiris Therapeutics for $660M

 Smith & Nephew to Acquire Osiris Therapeutics for $660M

Smith & Nephew to Acquire Osiris Therapeutics for $660M

Shots: 

  • Smith & Nephew acquires Osiris Therapeutics, in all stock transaction for $19/share at a premium of 37% making the total deal value $660M. The transaction is expected to close in Q2’19 with the joining of 360 employees to Smith & Nephew
  • The focus of an acquisition is to expand Smith & Nephew’s regenerative drugs portfolio and to enhance its wound management business with the usage of Osiris’ lead candidates Grafix & Stravix
  • Osiris’ Grafix & Stravix is a cryopreserved placental membrane & tissue used to heal wounds with exposed bone and tendon and to support tissue repair respectively

Click here to read full press release/ article | Ref: Smith & Nephew | Image: Morgan-Keller Construction

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post